EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia

Ahmad Aljohmani iD, Christian Herr, Martin Witzenrath, Linda Pätzold, Markus Bischoff, Philipp Wartenberg, Ulrich Boehm, Christoph Beisswenger, Qinghai Tian, Matthias W Laschke, Matthias Hannig, Claus-Michael Lehr und 3 weitere

European Respiratory Journal · 2026

DOI: 10.1183/13993003.02060-2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2026. Verfasst von Ahmad Aljohmani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Molecular Pharmacology and Center for Human and Molecular Biology (ZHMB), Saarland University, Homburg, Germany. Hauptthemen laut MEDLINE: ADAM10 Protein, ADAM17 Protein, COVID-19, Pneumonia, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pneumonia caused by viral or bacterial pathogens such as severe acute respiratory syndrome coronavirus 2 or Pseudomonas aeruginosa may result in life-threatening disease with a strong contribution of protease dysregulation. The present study aimed to systematically characterise the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia.

Methods

The analysis of coronavirus disease 2019 (COVID-19) and bacterial pneumonia patient samples was combined with in vivo experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies.

Results

Hospitalised bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a pre-clinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarisation, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level.

Conclusion

Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAM10 ProteinADAM17 ProteinCOVID-19Pneumonia, BacterialLeukocytesAmyloid Precursor Protein SecretasesPneumonia, ViralAnimalsMiceHumansExosomesMice, KnockoutSeverity of Illness IndexMaleSARS-CoV-2Disease Models, AnimalFemaleMembrane Proteins

Substanzen

ADAM10 ProteinADAM17 ProteinADAM10 protein, humanADAM17 protein, humanAmyloid Precursor Protein SecretasesAdam17 protein, mouseAdam10 protein, mouseMembrane Proteins

Autor:innen und Institutionen

  • Dept of Molecular Pharmacology and Center for Human and Molecular Biology (ZHMB), Saarland University, Homburg, Germany.
  • Center for Molecular Signaling (PZMS), and Center for Gender-sensible Biology and Medicine (CGBM), Saarland University, Homburg, Germany.
  • Dept for Internal Medicine V - Pulmonology, Allergology, Intensive Care Medicine, Saarland University, Homburg, Germany.
  • Dept of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Be…
  • Institute for Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
  • Dept of Experimental Pharmacology, Saarland University, Homburg, Germany.

ORCID-Profile: Ahmad Aljohmani, Robert Bals

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Aljohmani, A., Herr, C., Witzenrath, M., Pätzold, L., Bischoff, M., Wartenberg, P., Boehm, U., Beisswenger, C., Tian, Q., Laschke, M. W., Hannig, M., Lehr, C. M., Bals, R., Schilling, O., & Yildiz, D. (2026). Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia. European Respiratory Journal. https://doi.org/10.1183/13993003.02060-2024

Vancouver

Aljohmani A, Herr C, Witzenrath M, Pätzold L, Bischoff M, Wartenberg P, et al. Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia. European Respiratory Journal. 2026. doi:10.1183/13993003.02060-2024

BibTeX
@article{Aljohmani2026,
  author = {Aljohmani, Ahmad and Herr, Christian and Witzenrath, Martin and Pätzold, Linda and Bischoff, Markus and Wartenberg, Philipp and Boehm, Ulrich and Beisswenger, Christoph and Tian, Qinghai and Laschke, Matthias W and Hannig, Matthias and Lehr, Claus-Michael and Bals, Robert and Schilling, Oliver and Yildiz, Daniela},
  title = {Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia},
  journal = {European Respiratory Journal},
  year = {2026},
  doi = {10.1183/13993003.02060-2024}
}
Kostenlos starten →